Association of Community Cancer Centers Relaunches Immuno-Oncology Initiative to Meet Evolving Needs of Oncology Community

The Association of Community Cancer Centers (ACCC) announced today the relaunch of the ACCC Immuno-Oncology Institute including an online resource portal for oncology professionals to find practical, proactive strategies for the effective delivery of new and emerging therapies. ACCC worked closely with a team of multispecialty thought leaders via the IO Institute Working Groups to develop forward-thinking resources at the intersection of clinical science, care delivery, business, operations, and policy to support all facets of immunotherapy integration.
 
The ACCC Immuno-Oncology Institute is the only initiative dedicated to educating multidisciplinary teams to go beyond a clinical understanding of IO and tackle real-world implementation issues. With the care of patients on immunotherapies now extending beyond the cancer team, the ACCC Immuno-Oncology Institute is at the forefront of developing critical education to empower healthcare professionals across care delivery settings.
 
“As IO has advanced at a rapid pace, there was a need to evolve our Institute,” said Lee S. Schwartzberg, MD, FACP Chair, ACCC IO Institute Executive Committee. “From quick takeaways to a thought-provoking "Immuno-Oncology Insights" series; eLearning courses, webinars, and videos; and our comprehensive, end-of-year publication, the ACCC Immuno-Oncology Institute is developing an extensive collection of operational, clinical, and administrative tools that are designed to meet professional interests and demanding schedules.”
 
Resources available on the ACCC Immuno-Oncology Institute web portal address the following topics:
 Care Coordination & Communication

• Immune-Related Adverse Events
• Novel Therapies
• Policy & Reimbursement
• Managing Survivorship
• Tele-medicine & Virtual Navigation

 The ACCC Immuno-Oncology Institute is supported by Bristol-Myers Squibb; EMD Serono; Kite, a Gilead Company; and Merck & Co, Inc.